content_image/254558.jpg content_image/254555.jpg content_image/254561.jpg content_image/254562.jpg
Astellas has expansive coverage of the Asia & Oceania region. We currently have 10 sales subsidiaries in this region, following the establishment of a sales subsidiary in Singapore in July 2013. 

By working to maximize the value of our products, primarily through new drugs sold globally, we are aiming to sustain a high level of growth. 

In the course of expanding our business, we remain constantly mindful of the latest developments surrounding the different intellectual property and healthcare systems of each country. We are also working hard to recruit tal- ented human resources and further increase the motivation of employees by improving our corporate culture. 

China remains the driving force behind our high growth, supported by the efforts of about 760 MRs. In this manner, we are continuously increasing our sales force in the Asia & Oceania region. At the same time, we are working to upgrade our management systems, including compliance. 

## Sales of Major Products 

<img src='content_image/254558.jpg'>

## Continuous Product Introductions (Approvals and Launches) (2013.4–2014.6) 

<img src='content_image/254555.jpg'>

<img src='content_image/254561.jpg'>

<img src='content_image/254562.jpg'>

